Deborah Ricci
About
Deborah Ricci is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Cancer Research.
According to data from OpenAlex, Deborah Ricci has authored 51 papers receiving a total of 876 indexed citations (citations by other indexed papers that have themselves been cited), including 34 papers in Pulmonary and Respiratory Medicine, 19 papers in Oncology and 19 papers in Cancer Research. Recurrent topics in Deborah Ricci's work include Prostate Cancer Treatment and Research (31 papers), Radiopharmaceutical Chemistry and Applications (15 papers) and Cancer, Lipids, and Metabolism (10 papers). Deborah Ricci is often cited by papers focused on Prostate Cancer Treatment and Research (31 papers), Radiopharmaceutical Chemistry and Applications (15 papers) and Cancer, Lipids, and Metabolism (10 papers). Deborah Ricci collaborates with scholars based in United States, United Kingdom and Spain. Deborah Ricci's co-authors include Andrés Poveda, Trilok Parekh, Helgi van de Velde, Juan Carlos Tercero, Reyna Favis, Songbai Wang, Claudia Lebedinsky, Stanley B. Kaye, Bradley J. Monk and Robert McCormack and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer Research.
In The Last Decade
Deborah Ricci
47 papers receiving 864 citations
Peers
Deborah Ricci
Fabian Zohren United States
Gregory Friberg United States
L Pyle United Kingdom
Corrine Zarwan United States
Paola Aimone Switzerland
Elisa Zanardi Italy
Encarna Adrover Spain
Yu-Nien Sun United States
Eleni Timotheadou Greece
Bin Meng China
Citations per year, relative to Deborah Ricci Deborah Ricci (= 1×)
peers
Fabian Zohren
Countries citing papers authored by Deborah Ricci
Since
Specialization
Citations
This map shows the geographic impact of Deborah Ricci's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Deborah Ricci with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Deborah Ricci more than expected).
Fields of papers citing papers by Deborah Ricci
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Deborah Ricci. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Deborah Ricci. The network helps show where Deborah Ricci may publish in the future.
Co-authorship network of co-authors of Deborah Ricci
This figure shows the co-authorship network connecting the top 25 collaborators of Deborah Ricci. A scholar is included among the top collaborators of Deborah Ricci based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Deborah Ricci. Deborah Ricci is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Batech, Michael, Ann Madsen, Nicolle M. Gatto, et al.. (2025). Combining Real‐World and Clinical Trial Data Through Privacy‐Preserving Record Linkage: Opportunities and Challenges—A Narrative Review. Health Science Reports. 8(9). e71272–e71272.
2.
Nyaku, Mawuli, et al.. (2025). Effectiveness of Heterologous and Homologous Ad26.COV2.S Vaccine Boosting in Preventing COVID-19-Related Outcomes Among Individuals with a Completed Primary Vaccination Series in the United States. Vaccines. 13(2). 166–166.
3.
Boehme, Amelia K., Raymond A. Harvey, Ann Madsen, et al.. (2024). An observational post-authorization study to assess the effectiveness of a single dose Ad26.COV2.S for the prevention of COVID-19 using real-world data. Frontiers in Public Health. 12. 1501919–1501919.
4.
Smith, Matthew R., Shibu Thomas, Michael Gormley, et al.. (2021). Blood Biomarker Landscape in Patients with High-risk Nonmetastatic Castration-Resistant Prostate Cancer Treated with Apalutamide and Androgen-Deprivation Therapy as They Progress to Metastatic Disease. Clinical Cancer Research. 27(16). 4539–4548.
5.
Feng, Felix Y., Shibu Thomas, Fred Saad, et al.. (2021). Association of Molecular Subtypes With Differential Outcome to Apalutamide Treatment in Nonmetastatic Castration-Resistant Prostate Cancer. JAMA Oncology. 7(7). 1005–1005.
6.
Jayaram, Anuradha, Anna Wingate, Daniel Wetterskog, et al.. (2021). Plasma tumor gene conversions after one cycle abiraterone acetate for metastatic castration-resistant prostate cancer: a biomarker analysis of a multicenter international trial. Annals of Oncology. 32(6). 726–735.
7.
Efstathiou, Eleni, John W. Davis, Louis L. Pisters, et al.. (2019). Clinical and Biological Characterisation of Localised High-risk Prostate Cancer: Results of a Randomised Preoperative Study of a Luteinising Hormone-releasing Hormone Agonist with or Without Abiraterone Acetate plus Prednisone. European Urology. 76(4). 418–424.
8.
Chi, K.N., Shibu Thomas, Neeraj Agarwal, et al.. (2019). Androgen receptor (AR) aberrations in patients (Pts) with metastatic castration-sensitive prostate cancer (mCSPC) treated with apalutamide (APA) plus androgen deprivation therapy (ADT) in TITAN. Annals of Oncology. 30. v347–v348.
9.
Kohli, Manish, Liguo Wang, Scott M. Dehm, et al.. (2017). Association of Wnt pathway activation with prechemotherapy abiraterone acetate resistance in metastatic castration-resistant prostate cancer (mCRPC) by genome-wide analysis of metastases.. Journal of Clinical Oncology. 35(6_suppl). 175–175.
10.
Lam, Hung‐Ming, Ryan P. McMullin, Holly M. Nguyen, et al.. (2016). Characterization of an Abiraterone Ultraresponsive Phenotype in Castration-Resistant Prostate Cancer Patient-Derived Xenografts. Clinical Cancer Research. 23(9). 2301–2312.
11.
Klein, Eric A., Timothy C. Brand, Inger L. Rosner, et al.. (2016). A 17-gene genomic prostate score (GPS) as a predictor of biochemical (BCR) and clinical recurrence (CR) in men with surgically treated intermediate- and high-risk prostate cancer (PCa).. Journal of Clinical Oncology. 34(15_suppl). 5049–5049.
12.
Offner, Fritz, Olga Samoilova, Evgenii A. Osmanov, et al.. (2015). Frontline rituximab, cyclophosphamide, doxorubicin, and prednisone with bortezomib (VR-CAP) or vincristine (R-CHOP) for non-GCB DLBCL. Blood. 126(16). 1893–1901.
13.
Attard, Gerhardt, Johann S. de Bono, Christopher J. Logothetis, et al.. (2015). Improvements in Radiographic Progression-Free Survival Stratified by ERG Gene Status in Metastatic Castration-Resistant Prostate Cancer Patients Treated with Abiraterone Acetate. Clinical Cancer Research. 21(7). 1621–1627.
14.
Monk, B.J., Prafull Ghatage, Trilok Parekh, et al.. (2015). Effect of BRCA1 and XPG mutations on treatment response to trabectedin and pegylated liposomal doxorubicin in patients with advanced ovarian cancer: exploratory analysis of the phase 3 OVA-301 study. Annals of Oncology. 26(5). 914–920.
15.
Ludwig, Heinz, Luísa Viterbo, Richard Greil, et al.. (2012). Randomized Phase II Study of Bortezomib, Thalidomide, and Dexamethasone With or Without Cyclophosphamide As Induction Therapy in Previously Untreated Multiple Myeloma. Journal of Clinical Oncology. 31(2). 247–255.
16.
Poveda, Andrés, Stanley B. Kaye, Robert McCormack, et al.. (2011). Circulating tumor cells predict progression free survival and overall survival in patients with relapsed/recurrent advanced ovarian cancer. Gynecologic Oncology. 122(3). 567–572.
17.
Ricci, Deborah, et al.. (2011). Global Requirements for DNA Sample Collections: Results of a Survey of 204 Ethics Committees in 40 Countries. Clinical Pharmacology & Therapeutics. 89(4). 554–561.
18.
Favis, Reyna, Yu Sun, Helgi van de Velde, et al.. (2011). Genetic variation associated with bortezomib-induced peripheral neuropathy. Pharmacogenetics and Genomics. 21(3). 121–129.
19.
Buda, Gabriele, Deborah Ricci, Reyna Favis, et al.. (2010). Polymorphisms in the multiple drug resistance protein 1 and in P-glycoprotein 1 are associated with time to event outcomes in patients with advanced multiple myeloma treated with bortezomib and pegylated liposomal doxorubicin. Annals of Hematology. 89(11). 1133–1140.
20.
Poveda, Andrés, Stuart Kaye, Robert McCormack, et al.. (2009). Circulating tumor cells (CTC) in a study of relapsed/recurrent advanced ovarian cancer: An exploratory analysis in the ova-301 phase III study of pegylated liposomal doxorubicin (PLD) compared with trabectedin and PLD. Journal of Clinical Oncology. 27(15_suppl). 5551–5551.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Fabian Zohren Breakdown of academic impact, for papers by Gregory Friberg Breakdown of academic impact, for papers by L Pyle Breakdown of academic impact, for papers by Corrine Zarwan Breakdown of academic impact, for papers by Paola Aimone Breakdown of academic impact, for papers by Elisa Zanardi Breakdown of academic impact, for papers by Encarna Adrover Breakdown of academic impact, for papers by Yu-Nien Sun Breakdown of academic impact, for papers by Eleni Timotheadou Breakdown of academic impact, for papers by Bin Meng